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Abstract
Background: A randomized controlled trial in South Africa found a beneficial effect of acyclovir on genital ulcer healing, but
no effect was seen in trials in Ghana, Central African Republic and Malawi. The aim of this paper is to assess whether the
variation in impact of acyclovir on ulcer healing in these trials can be explained by differences in the characteristics of the
study populations.
Methodology/Principal Findings: Pooled data were analysed to estimate the impact of acyclovir on the proportion of
ulcers healed seven days after randomisation by HIV/CD4 status, ulcer aetiology, size and duration before presentation; and
impact on lesional HIV-1. Risk ratios (RR) were estimated using Poisson regression with robust standard errors. Of 1478
patients with genital ulcer, most (63%) had herpetic ulcers (16% first episode HSV-2 ulcers), and a further 3% chancroid, 2%
syphilis, 0.7% lymphogranuloma venereum and 31% undetermined aetiology. Over half (58%) of patients were HIV-1
seropositive. The median duration of symptoms before presentation was 6 days. Patients on acyclovir were more likely to
have a healed ulcer on day 7 (63% vs 57%, RR = 1.08, 95% CI 0.98–1.18), shorter time to healing (p = 0.04) and less lesional
HIV-1 RNA (p = 0.03). Small ulcers (,50 mm2), HSV-2 ulcers, first episode HSV-2 ulcers, and ulcers in HIV-1 seropositive
individuals responded best but the better effectiveness in South Africa was not explained by differences in these factors.
Conclusions/Significance: There may be slight benefit in adding acyclovir to syndromic management in settings where
most ulcers are genital herpes. The stronger effect among HIV-1 infected individuals suggests that acyclovir may be
beneficial for GUD/HIV-1 co-infected patients. The high prevalence in this population highlights that genital ulceration in
patients with unknown HIV status provides a potential entry point for provider-initiated HIV testing.
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Introduction
Herpes simplex virus-2 (HSV-2) is the most common cause of
genital ulcer disease (GUD) worldwide [1]. The natural course of
genital herpes consists of subclinical genital viral shedding and
clinical recurrences of blisters and ulcers which occur on the vulva,
vagina or cervix in women, and on the glans, prepuce or shaft of
the penis in men. The first episode of genital herpes is usually the
most severe, lasting 2 to 4 weeks if untreated, and subsequent
recurrences last 7 to 12 days without treatment [2]. A study
conducted in the 1980s reported that oral acyclovir significantly
reduced viral shedding, improved ulcer healing and decreased the
incidence of new lesion formation among patients with recurrent
genital herpes who received treatment within 48 hours of the onset
of lesions [3]. A similar effect was seen on first episode genital
herpes [4]. In 2003, the World Health Organization (WHO)
published sexually transmitted infections (STI) treatment guide-
lines recommending addition of acyclovir to syndromic manage-
ment of GUD in countries where the prevalence of HSV-2 as a
GUD aetiology exceeds 30% [5]. However, a recent survey
conducted in eight African countries found that acyclovir was
rarely available in public health facilities, mainly due to cost and
regulatory barriers [6].
The effectiveness of adding acyclovir to syndromic management
for GUD in Africa was recently evaluated in three randomized
controlled trials (RCTs). Two of the trials, one among women in
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Ghana and Central African Republic (CAR) and one among both
men and women in Malawi, found no impact of standard dose
acyclovir on ulcer healing [7–8]. However, a trial among South
African men found that healing was significantly faster among
those in the acyclovir arm (61% vs 42% healed at day 7; p= 0.003)
[9] and acyclovir is now included in the guidelines for first-line
management of GUD in South Africa [10].
In this paper, we analyze pooled data from the three RCTs to
assess whether the variation in impact of acyclovir on ulcer healing
can be explained by differences in the characteristics of the study
populations in this large series of patients presenting with GUD in
four distinct African settings.
Methods
Details of the three individual trials have been reported
elsewhere [7–9] (Trials registration numbers: NCT00158483,
ISRCTN32121857, NCT00164424). The trials had similar
designs, with an a-priori plan to conduct pooled analyses. Briefly,
in each trial, consenting consecutive patients with clinically
confirmed GUD were enrolled and randomized to either acyclovir
or placebo (400 mg three times daily for 5 days for Ghana/CAR
and South Africa; 800 mg two times daily for 5 days in Malawi).
Patients with very large ulcers (surface area $500 mm2) and those
with long ulcer duration (.21 days) were not included in the trial
in Ghana/CAR and were treated immediately with acyclovir
instead. Participants were asked to return for follow-up on day 2
and/or 4, day 7, day 10 (South Africa only), day 14 and day 28.
The primary outcomes in this analysis were the impact of
acyclovir on the proportion of ulcers healed and lesional HIV-1
RNA (in HIV-1 seropositive patients) at 7 days post-randomiza-
tion (defined as visits occurring on days 6–8 inclusive). The
secondary outcome was time to ulcer healing over the 28 days of
follow-up.
Ulcer healing was defined as a reduction in the size (in mm2) of
the largest ulcer at baseline by at least 90%. Further analyses used
absolute ulcer size (,10 mm2) as the outcome. Thresholds for
detectable lesional HIV-1 RNA were 50 copies/mL for South
Africa, 250 copies/mL for Ghana/CAR, and 400 copies/mL for
Malawi. Ulcers which were not sampled because they were healed
were assumed to have undetectable lesional HIV-1 RNA.
Sub-groups of interest were defined a-priori as follows:
i) Ulcer aetiology (HSV ulcer, non-HSV ulcer, first episode
HSV-2 ulcer, recurrent HSV-2 ulcer). First episode HSV-2
ulcers are defined as HSV-2 seronegative patients with
HSV-2 DNA detected in the lesion. Six patients who had
an HSV-1 ulcer without evidence of lesional HSV-2
infection were included as HSV ulcers.
ii) Duration of symptoms before presentation (#2 days, 3–4
days, 5–6 days, .=7 days).
iii) Size of ulcer at baseline (,50 mm2, $50 mm2).
iv) HIV/CD4 status: (HIV seronegative, HIV-1 seropositive
with CD4 .500 cells/mm3; HIV-1 seropositive with CD4
200–500 cells/mm3; HIV-1 seropositive with CD4 ,200
cells/mm3). Too few patients were on antiretroviral therapy
to analyse these separately.
Statistical analyses were conducted in Stata 11.0 (StataCorp,
Texas, USA). Poisson regression with robust standard errors was
used to estimate risk ratios (RR) and 95% confidence intervals (CI)
[11]. The risk difference and 95%CI for the primary analysis was
also estimated, using binomial methods. Time-to-ulcer-healing was
assessed graphically using Kaplan-Meier analysis and a log-rank
test was used to obtain a p-value for a difference in time-to-healing
by arm. The Kruskal-Wallis test was used to compare median
durations between study sites. To investigate whether the
differential effect of acyclovir in South Africa could be explained
by factors associated with ulcer healing, we stratified analyses by
South Africa versus non South Africa sites and tested for effect-
modification by site. To allow for imbalances between arms, risk
ratios of the impact of acyclovir were adjusted for factors
potentially associated with ulcer healing (ulcer aetiology, size,
duration of symptoms before enrolment and HIV status).
Ethics statement
Each trial was approved by the ethics committee of the London
School of Hygiene and Tropical Medicine, and the following local
ethics committees and institutional review boards: ANRS 1212 -
ethics committees of the Ministries of Health of Ghana and the
Central African Republic; Malawi trial - National Health Sciences
Research Committee in Malawi and the ethics committees of
University of North Carolina and the US Centers for Disease
Control and Prevention (CDC); South Africa - ethics committees
and institutional review boards of the University of the
Witwatersrand, the CDC, and the Gauteng Provincial and City
of Johannesburg Health Departments. All participants provided
written informed consent.
Results
Characteristics of GUD patients
Of the 1516 GUD patients eligible for the three trials, 1478
were randomized (550 female and 928 male). The flow of
participants through the trials is shown in Figure 1. Socio-
demographic and behavioural characteristics of the participants
are shown in Table 1 (by trial arm) and Table 2 (by site). There
was good balance in characteristics by trial arm (Table 1). The
median age of participants was 28 years (interquartile range 24–34
years), and this was similar by study site and sex. Overall, almost
half of men (47%) and one-third of women (33%) reported having
had a previous GUD in the past year (Table 2). At the enrolment
visit, the median number of ulcers per patient was two in each
country, and women in Ghana and CAR tended to have fewer
ulcers than patients in Malawi and South Africa. The size of the
largest ulcer was measured for each patient, and varied
considerably, with median size being smallest in Malawi
(21 mm2 and 28 mm2 respectively in women and men), and
largest in Ghana and CAR (147 mm2 and 130 mm2, respectively),
despite exclusion of ulcers $500 mm2 in these sites. The median
time from first symptoms to presentation was 6 days, and this was
slightly shorter in South Africa and Ghana (5 days) than among
women in CAR and women in Malawi (7 days; p = 0.0001).
Overall, 28% of women and 13% of men were on antibiotics for
the current ulcer, including 43% of women in CAR.
HIV-1 seroprevalence was high in all sites, ranging from 34%
among women in Ghana to 77% among Malawian women
(Table 3). Among HIV-1 infected persons, mean HIV-1 plasma
viral load was 4.77 log10 copies/mL (95% CI 4.71–4.84) overall,
but varied significantly between site (p,0.0001), being lowest in
Ghana (4.26 log10 copies/mL), where the proportion of partici-
pants with CD4 count above 500 cells/mm3 was also highest
(38%). Overall, almost half of HIV-1 seropositive women (47%),
and a third of HIV-1 seropositive men (34%) presented with CD4
counts below 200 cells/mm3. Despite this, the proportion of HIV-
1 seropositive participants on antiretroviral therapy was low (9%
in women, 3% in men). Overall, about half of the HIV-1
seropositive participants had detectable lesional HIV-1 RNA at
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enrollment, but this varied substantially by site (from 31% among
women in Malawi to 80% in CAR; p,0.0001).
HSV-2 seroprevalence was 74% overall, and varied significantly
by site, being highest among women in CAR (95%) and Malawi
(81%) compared to women in Ghana and men in Malawi and
South Africa (69–71%) (p,0.0001). Overall, about two-thirds of
ulcers had detectable HSV DNA (type 1 or 2) alone or in
combination with other pathogens, making this the most common
ulcer aetiology (Figure 2). Of the 930 HSV ulcers, 6 had detectable
HSV-1 DNA only (one from Ghana, 5 from South Africa), and the
remaining 924 had detectable HSV-2 DNA. Of these, 225 (24%)
ulcers were first episode HSV-2 ulcers, 693 (76%) had recurrent
HSV-2 ulcers and the remaining 6 had unknown HSV-2
serostatus. A total of 154 participants (10.4%) had at least one
lesional bacterial infection detected, and 90 participants (6.1%)
had bacterial infections only. Prevalence of chancroid was 4.9%
(n= 73), syphilis 3.5% (n= 52), and lymphogranuloma venereum
2.2% (n= 33), whilst 435 ulcers (30%) had undefined or unknown
aetiology.
Impact of acyclovir on ulcer healing
Of the 1478 patients enrolled, 1258 (85%) were seen on day 7,
of whom 1255 had a genital examination (Figure 1). The
proportion seen was similar by site (ranging from 82% among
Malawian women to 89% in women in CAR) and by arm (85% in
each arm).
Overall, there was a small impact of acyclovir on the proportion
of ulcers healed on day 7 (63% vs. 57% in acyclovir and placebo
arms respectively; RR=1.10, 95% CI 1.00–1.20; risk differ-
ence = 5.7%, 95% CI 0.3%–11.1; Table 4). Adjustment for factors
potentially associated with ulcer healing rate (GUD aetiology, size
of ulcer at baseline, duration before presentation, and HIV/CD4
Figure 1. CONSORT flow diagram of eligibility, enrolment and follow-up in three African randomized controlled trials of episodic
therapy for genital herpes.
doi:10.1371/journal.pone.0022601.g001
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status) made little difference (adjusted RR (aRR) = 1.08, 95% CI
0.98–1.18). The impact on healing was greatest in South Africa
(aRR=1.21, 95% CI 1.05–1.40) compared with other sites
(aRR=0.98, 95% CI 0.87–1.10) with evidence of effect-measure
modification of these adjusted risk ratios (p-interaction = 0.02).
Overall, individuals randomized to the acyclovir arm had slightly
faster healing (p= 0.04), principally due to the South African trial
where time to healing was significantly improved (p = 0.007;
Figure 3b). Acyclovir had little impact on time to healing in the
other sites (p = 0.76; Figure 3a). Results were similar if ulcer
size,10 mm2 was used as the outcome (results not shown).
As expected, acyclovir was associated with improved healing on
day 7 among individuals with HSV ulcers compared to those with
non-HSV ulcers (aRR=1.15; 95% CI 1.03–1.29 and aRR=0.94;
95% CI 0.81–1.09; p-interaction = 0.04; Table 4). However, the
effect on healing of HSV ulcers was seen only in South Africa
(South Africa: aRR=1.30, 95% CI 1.09–1.55; other sites:
aRR=1.03, 95% CI 0.89–1.20; p-interaction = 0.05). The impact
was strongest for first episode HSV-2 ulcers (aRR=1.26, 95% CI
1.00–1.57), and again the effect was limited to South Africa (South
Africa: aRR=1.43, 95% CI 0.98–2.09; other sites: aRR=1.07,
95% CI 0.83–1.37; p-interaction = 0.12).
There was little difference in impact of acyclovir by duration of
symptoms before presentation, but acyclovir had a better impact
on healing of small ulcers than larger ulcers (p-interaction = 0.002;
Table 4). Again, differences persisted between South African and
the other sites (aRR for small ulcers in South Africa = 1.33, 95%
CI 1.13–1.55; aRR for small ulcers in other sites = 1.10, 95% CI
0.95–1.26; p-interaction = 0.09).
The effect of acyclovir was slightly stronger among HIV-1
seropositive individuals (aRR=1.16, 95% CI 1.01–1.32; Table 4)
than HIV-uninfected individuals (aRR=1.02, 95% CI 0.90–1.14).
The effect among HIV-1 seropositive individuals was largely due
to an effect in South Africa (aRR=1.31, 95% CI 1.06–1.60)
rather than in other sites (aRR=1.08, 95% CI 0.90–130),
although this difference was not significant (p-interaction = 0.17).
A similar pattern was seen when analyses were restricted to HIV-1
seropositive individuals with HSV-2 ulcers (Figure 3c and 3d). In
this subgroup, there was evidence of an impact overall
(aRR=1.20, 95% CI 1.02–1.41) but this was only seen in South
Africa (aRR=1.46, 95% CI 1.16–1.85) and not in other sites
(aRR=0.98, 95% CI 0.78–1.2; p-interaction = 0.03).
Impact of acyclovir on lesional HIV-1 RNA
Of the 726 HIV-1 seropositive individuals who were seen on
Day 7, data on lesional HIV-1 RNA was available for 667 (92%)
(Table 5). Overall, there was evidence of an impact of the
intervention on detectable lesional HIV-1 RNA after adjusting for
ulcer aetiology, size of ulcers, duration of symptoms and CD4
group (aRR=0.73, 95%CI:0.55–0.98). Again, the impact was
confined to South Africa (aRR=0.58, 95% CI 0.39–0.84), with no
evidence of an effect at other sites (aRR=1.01, 95% CI 0.65–1.57;
p–interaction = 0.05; results not shown).
Among the 466 HIV-1 seropositive individuals with HSV
ulcers, there was strong evidence of an effect on the intervention
on reducing prevalence of detectable lesional HIV-1 RNA
(aRR=0.66, 95% CI 0.47–0.92) and this was greater among the
64 participants with first episode HSV-2 ulcers (aRR=0.20, 95%
CI 0.03–1.11) compared to the effect among the 401 participants
with recurrent HSV-2 ulcers (aRR=0.74, 95% CI 0.52–1.02),
although this difference was not significant (p-interaction = 0.13).
The impact on both types of HSV-2 ulcers was stronger in South
Africa, although the differences were not significant.
The impact on lesional HIV-1 RNA was also stronger in those
presenting within a week of symptoms (RR=0.54, 95% CI 0.33–
0.90) and those with small ulcers (RR=0.55, 95% CI 0.31–0.87).
Overall, there was no evidence of an impact among the patients
with CD4 counts above 500 cells/mm3 or below 200 cells/mm3,
Table 1. Demographic, behavioural and clinic characteristics
of 1478 trial participants with genital ulcer disease (GUD) at
enrolment, by trial arm.
Placebo
arm
Acyclovir
arm Total
Total N=740 N=736 N=1478
n (%) n (%) n (%)
Male 465 (63%) 463 (63%) 928 (63%)
Age, years
15–24 191 (26%) 210 (29%) 401 (27%)
25–34 368 (50%) 368 (50%) 736 (50%)
.= 35 181 (25%) 158 (21%) 339 (23%)
Marital status
Single 356 (48%) 344 (47%) 700 (47%)
Married 292 (39%) 305 (41%) 597 (40%)
Sep/div/widow 92 (12%) 87 (12%) 179 (12%)
Education
Primary or lower 274 (37%) 289 (39%) 563 (38%)
Secondary or higher 464 (63%) 447 (61%) 911 (62%)
Number of partners in last 3 months
None 154 (21%) 155 (21%) 309 (21%)
1 387 (53%) 383 (52%) 770 (52%)
2–9 165 (22%) 157 (23%) 332 (23%)
.= 10 30 (4%) 29 (4%) 59 (4%)
New partner in last 3 monthsa 131 (30%) 137 (32%) 268 (31%)
Sex for money/giftsb 150 (20%) 136 (18%) 286 (19%)
GUD in past year 313 (43%) 294 (40%) 607 (42%)
Number of ulcers
1 263 (36%) 269 (37%) 532 (37%)
2 158 (22%) 164 (23%) 322 (22%)
3 122 (17%) 90 (12%) 212 (15%)
.= 4 184 (25%) 204 (28%) 388 (27%)
Size of largest ulcer,mm2
,50 381 (52%) 404 (55%) 785 (53%)
50–149 189 (26%) 190 (26%) 379 (26%)
150–299 111 (15%) 89 (12%) 200 (14%)
300–500 55 (7%) 51 (7%) 106 (7%)
Duration of symptoms at presentation
1–2 days 45 (6%) 51 (7%) 96 (7%)
3–4 days 204 (28%) 222 (31%) 426 (29%)
5–6 days 128 (18%) 110 (15%) 238 (16%)
1 week + 351 (48%) 340 (47%) 691 (47%)
On antibiotics 143 (19%) 132 (18%) 275 (19%)
HSV ulcer 471 (65%) 459 (63%) 930 (64%)
HIV-1 seropositive 433 (59%) 414 (56%) 847 (58%)
aThis question was not asked in the South African trial.
bFor Ghana and CAR, this is current occupation as a sex worker. In Malawi and
South Africa, the question refers to ever having exchanged sex for money.
doi:10.1371/journal.pone.0022601.t001
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Table 2. Demographic, behavioural and clinic characteristics of 1478 trial participants with genital ulcer disease (GUD) at
enrolment, by country and sex.
Ghana Females CAR Females
Malawi
Females Malawi Males S Africa Males All females All males
Total N=284 N=157 N=109 N=313 N=615 N=550 N=928
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age, years
15–24 110 (39%) 48 (31%) 40 (37%) 73 (23%) 130 (21%) 198 (36%) 203 (22%)
25–34 104 (37%) 75 (48%) 48 (44%) 186 (59%) 323 (53%) 227 (41%) 509 (55%)
.= 35 68 (24%) 34 (22%) 21 (19%) 54 (17%) 162 (26%) 123 (22%) 216 (23%)
Median (IQRa) 27 (23–34) 29 (23–34) 28 (23–33) 28 (25–33) 29 (25–35) 28 (23–34) 29 (25–34)
Marital status
Single 163 (58%) 52 (33%) 16 (15%) 115 (37%) 354 (58%) 231 (42%) 469 (51%)
Married 72 (26%) 60 (38%) 62 (57%) 164 (52%) 239 (39%) 194 (35%) 403 (43%)
Sep/div/widow 47 (17%) 45 (29%) 31 (28%) 34 (11%) 22 (4%) 123 (22%) 56 (6%)
Education
Primary or lower 131 (47%) 76 (48%) 59 (54%) 160 (51%) 137 (22%) 266 (49%) 297 (32%)
Secondary or higher 150 (53%) 81 (52%) 50 (46%) 153 (49%) 477 (78%) 281 (51%) 630 (68%)
Number of partners in last 3 months
None 99 (35%) 130 (83%) 14 (13%) 20 (6%) 46 (8%) 243 (44%) 66 ((47%)
1 107 (38%) 22 (14%) 75 (69%) 185 (59%) 381 (62%) 204 (37%) 566 (61%)
2–9 22 (8%) 3 (2%) 19 (17%) 108 (35%) 180 (30%) 44 (8%) 288 (31%)
.= 10 54 (19%) 2 (1%) 0 (0%) 0 (0%) 3 (0.5%) 56 (11%) 3 (,1%)
New partner in last 3 monthsb 79 (28%) 10 (6%) 21 (19%) 158 (50%) n/a 110 (20%) 158 (50%)
Sex for money/giftsc 59 (21%) 8 (5%) 21 (19%) 119 (38%) 79 (13%) 88 (16%) 198 (21%)
Reported GUD in past year 79 (28%) 63 (40%) 40 (37%) 117 (37%) 308 (52%) 186 (33%) 425 (47%)
Number of ulcers
1 117 (42%) 70 (45%) 31 (28%) 100 (32%) 214 (36%) 218 (40%) 314 (35%)
2 79 (28%) 45 (29%) 26 (24%) 58 (19%) 114 (19%) 150 (28%) 172 (19%)
3 54 (19%) 21 (13%) 16 (15%) 44 (14%) 77 (13%) 91 (17%) 121 (13%)
.= 4 28 (10%) 21 (13%) 36 (33%) 111 (35%) 192 (33%) 85 (16%) 303 (33%)
Median (IQR) 2 (1–3) 2 (1–3) 2 (1–4) 2 (1–5) 2 (1–4) 2 (1–3) 2 (1–4)
Size of largest ulcer,mm2
,50 101 (36%) 18 (11%) 72 (66%) 200 (64%) 394 (64%) 191 (35%) 594 (64%)
50–149 50 (18%) 80 (51%) 30 (28%) 76 (24%) 143 (23%) 160 (29%) 219 (24%)
150–299 69 (24%) 48 (31%) 6 (6%) 22 (7%) 55 (9%) 123 (22%) 77 (8%)
300–500 62 (22%) 11 (7%) 1 (1%) 11 (4%) 21 (3%) 74 (14%) 32 (3%)
Median (IQR) 147
(30–290)
130
(80–195)
21
(12–50)
28
(12–75)
35
(15–81)
100
(28–221)
32
(15–79)
Duration of symptoms at presentation
1–2 days 22 (8%) 3 (2%) 5 (5%) 17 (5%) 49 (8%) 30 (6%) 66 (7%)
3–6 days 145 (52%) 46 (30%) 43 (42%) 141 (45%) 289 (48%) 234 (44%) 430 (47%)
1 week + 84 (30%) 45 (29%) 24 (23%) 67 (21%) 158 (26%) 153 (28%) 225 (25%)
2 weeks + 20 (7%) 32 (21%) 15 (15%) 40 (13%) 79 (13%) 67 (12%) 119 (13%)
3 weeks + 8 (3%) 29 (19%) 16 (16%) 48 (15%) 26 (4%) 53 (10%) 74 (8%)
Median days (IQR) 5 (3–7) 7 (5–15) 7 (4–14) 6 (6–14) 5 (3–8) 7 (4–10) 6 (4–10)
On antibiotics 60 (21%) 68 (43%) 24 (22%) 68 (22%) 55 (9%) 152 (28%) 123 (13%)
aInterquartile range.
bThis question was not asked in the South African trial.
cFor Ghana and CAR, this is current occupation as a sexworker. In Malawi and South Africa, the question refers to ever having exchanged sex for money.
doi:10.1371/journal.pone.0022601.t002
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Table 3. HIV/HSV-related characteristics of trial participants with genital ulcer disease (GUD) at enrolment, by country & sex.
Ghana
Females
CAR
Females
Malawi
Females Malawi Males
S Africa
Males All females All males
Total N=284 N=157 N=109 N=313 N=615 N=550 N=928
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
HIV-1 seropositive 95 (34%) 108 (69%) 84 (77%) 173 (55%) 387 (63%) 287 (53%) 560 (60%)
Mean plasma viral load, log10 copies/mL
a
(95%CI)
4.26
(4.01–4.51)
4.95
(4.71–5.19)
4.74
(4.55–4.93)
4.90
(4.78–5.02)
4.80
(4.72–4.88)
4.66
(4.53–4.80)
4.83
(4.77–4.90)
CD4 counta,b, cells/mm3
.500 28 (38%) 10 (24%) 6 (8%) 23 (15%) 59 (15%) 44 (23%) 82 (15%)
200–500 19 (26%) 10 (24%) 27 (36%) 80 (51%) 196 (51%) 56 (29%) 276 (51%)
,200 26 (36%) 22 (52%) 42 (56%) 54 (34%) 130 (34%) 90 (47%) 184 (34%)
Median CD4 (IQR) 361
(138–611)
193
(70–479)
173
(84–347)
263
(151–409)
282
(165–419)
223
(104–467)
279
(164–417)
On antiretroviralsa,c 7 (7%) 12 (11%) 7 (8%) 5 (3%) 9 (3%) 26 (9%) 14 (3%)
Detectable lesional HIV-1 RNA1,d 11/31
(35%)
84/105
(80%)
24/78
(31%)
82/164
(50%)
173/379
(46%)
119/214
(56%)
255/543
(47%)
HSV-2 seropositive 198 (71%) 149 (95%) 85 (81%) 214 (69%) 434 (71%) 430 (79%) 648 (70%)
HSV ulcer (HSV-1 or HSV-2) 120 (45%) 92 (59%) 83 (76%) 184 (59%) 451 (74%) 295 (56%) 635 (69%)
HSV-2 ulcer 119 (45%) 92 (59%) 83 (76%) 184 (59%) 446 (73%) 294 (55%) 630 (58%)
First episode HSV-2 ulcere 19 (7%) 5 (3%) 10 (9%) 57 (18%) 134 (22%) 34 (6%) 191 (21%)
HIV-1 seropositive with HSV-2 ulcer 52 (19%) 64 (41%) 67 (61%) 112 (36%) 293 (48%) 183 (34%) 405 (44%)
Detectable lesional HIV-1 RNA in HIV-1
seropositive patients with HSV-2 ulcersf
9 (47%) 53 (84%) 21 (33%) 48 (44%) 120 (42%) 83 (57%) 168 (43%)
aAmong HIV seropositive individuals.
bMissing CD4 data for 22/95 HIV positive women in Ghana; 66/108 in CAR: 9/84 women in Malawi,16/173 men in Malawi, 2/387 men in South Africa.
cMissing ARV data for 1/95 women in Ghana and 54/387 men in South Africa.
dUses threshold of: 250 copies/mL for Ghana & CAR; 400 copies/mL for Malawi; 50 copies/mL for S Africa. Lesional HIV-1 RNA only.
eDefined as HSV-2 seronegative and HSV-2 DNA detected in the ulcer. Data are missing for 27 participants (21 with missing ulcer aetiology, 6 with missing HSV-2
serostatus).
fAmong 541 HIV-1 seropositive individuals with HSV-2 ulcers and data on lesional HIV-1 RNA.
doi:10.1371/journal.pone.0022601.t003
Figure 2. Ulcer aetiology in genital ulcer disease patients in Sub-Saharan African trials, by country and sex.
doi:10.1371/journal.pone.0022601.g002
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but strong evidence of reduced lesional HIV-1 RNA associated
with acyclovir among those with CD4 counts between 200 and
500 cells/mm3 (adjusted RR=0.48, 95% CI 0.29–0.80). There
was no evidence of interaction by site, but in the South African
patients, there was a protective effect of acyclovir in each CD4
group (CD4.500 cells/mm3: RR=0.69, 95% CI 0.11–4.31; CD4
200–500 cells/mm3: RR=0.34, 95% CI 0.17–0.68; CD4,200
cells/mm3: RR=0.84, 95% CI 0.53–1.32). By contrast, little effect
was observed in the non-South African patients (CD4.500 cells/
mm3: RR=3.47, 95% CI 0.33–36.36; CD4 200–500 cells/mm3:
RR=0.74, 95% CI 0.35–1.57; CD4,200 cells/mm3: RR=0.87;
95% CI 0.48–1.55).
Discussion
Herpes simplex virus type 2 is a recognised and important co-
factor of the HIV epidemic [1,12–14]. A number of RCTs have
failed to demonstrate an impact of HSV suppressive treatment on
acquisition [15–16] or transmission [17] of HIV, although
acyclovir or valacyclovir have been shown to decrease plasma
and genital HIV levels [18–24] and even to modestly reduce HIV
disease progression [25]. A meta-analysis of 8 RCTs showed that
high dose acyclovir ($3200 mg/day) significantly reduced mor-
tality among HIV-infected individuals [26]. In this pooled analysis
of episodic therapy trials, there was a small impact of acyclovir on
the proportion of ulcers healed on day 7 and this was more
substantial among patients with HSV ulcers, first episode HSV-2
ulcers, small ulcers, and HIV-1 seropositive individuals with CD4
counts between 200 and 500 cells/mm2. However, the impact was
consistently greater in South Africa than in other sites, and this
was not explained by different distributions of these clinical
characteristics.
It is challenging to explain the greater impact of acyclovir on
ulcer healing and lesional HIV in South Africa compared with
other sites. The acyclovir regimen was the same in South Africa as
in Ghana and Central African Republic (400 mg three times daily
Table 4. Impact of acyclovir on ulcer healing1 at Day 7 among 1255 trial participants.
N (seen
at Day 7)
Placebo
n (% healed)
Acyclovir
n (% healed)
Risk ratio
(95% CI)
Adjusted risk ratio
(95% CI)2
Total N=628 N=627
All patients 1255 358 (57%) 393 (63%) 1.10 (1.00–1.20) 1.08 (0.98–1.18)
Country and sex P-int3 = 0.02 P-int = 0.06
Ghana Females 243 99 (81%) 97 (80%) 0.99 (0.87–1.12) 1.00 (0.88–1.14)
CAR Females 139 25 (34%) 23 (35%) 1.02 (0.64–1.61) 0.80 (0.43–1.48)
Malawi Females 88 30 (70%) 32 (70%) 1.01 (0.76–1.31) 1.00 (0.73–1.35)
Malawi Males 273 72 (53%) 73 (54%) 1.02 (0.82–1.28) 0.99 (0.80–1.23)
South Africa Males 512 133 (52%) 168 (65%) 1.24 (1.07–1.44) 1.21 (1.05–1.40)
By ulcer aetiology at presentation P-int = 0.044 P-int = 0.044
Non HSV ulcer 450 135 (62%) 141 (61%) 0.98 (0.84–1.13) 0.94 (0.81–1.09)
HSV ulcer 788 212 (53%) 246 (63%) 1.19 (1.06–1.34) 1.15 (1.03–1.29)
First episode HSV-2 ulcer 188 54 (56%) 61 (68%) 1.22 (0.98–1.54) 1.26 (1.00–1.57)
Recurrent HSV-2 ulcer 593 156 (52%) 183 (62%) 1.18 (1.03–1.36) 1.14 (1.00–1.30)
HSV-2 ulcer only 736 201 (53%) 231 (64%) 1.21 (1.07–1.36) 1.17 (1.04–1.32)
HSV-2 plus bacterial infection 46 11 (55%) 15 (58%) 1.05 (0.62–1.77) 0.94 (0.57–1.55)
By duration before presentation P-int = 0.55 P-int = 0.35
1–2 days 78 26 (72%) 30 (71%) 0.99 (0.75–1.31) 1.09 (0.85–1.40)
3–4 days 360 115 (64%) 132 (73%) 1.15 (1.00–1.32) 1.11 (0.97–1.28)
5–6 days 209 69 (63%) 61 (62%) 0.98 (0.79–1.21) 0.93 (0.75–1.15)
$7 days 587 141 (48%) 160 (54%) 1.13 (0.97–1.33) 1.14 (0.97–1.34)
By size of ulcer at baseline P-int = 0.002 P-int = 0.002
,50 mm2 663 196 (60%) 253 (74%) 1.23 (1.11–1.37) 1.20 (1.08–1.34)
.= 50 mm2 590 162 (53%) 140 (49%) 0.91 (0.78–1.07) 0.88 (0.74–1.03)
By HIV/CD4 status (cells/mm3) P-int = 0.13 P-int = 0.15
HIV uninfected 524 174 (69%) 188 (70%) 1.02 (0.91–1.14) 1.02 (0.90–1.14)
HIV-1 infected 726 182 (49%) 202 (57%) 1.16 (1.02–1.33) 1.16 (1.01–1.32)
HIV-1 infected, CD4$500 101 33 (60%) 27 (59%) 0.98 (0.71–1.36) 0.99 (0.74–1.31)
HIV-1 infected, CD4 200–500 275 64 (49%) 91 (63%) 1.29 (1.04–1.60) 1.25 (1.02–1.53)
HIV-1 infected CD4,200 249 64 (50%) 62 (52%) 1.03 (0.81–1.32) 1.00 (0.79–1.27)
1Defined as a .=90% reduction in size of largest ulcer from enrolment.
2Risk ratio for impact of acyclovir among people in that strata, adjusted for all other variables in the table (ulcer aetiology is categorised as non-HSV ulcer, HSV ulcer).
3P-value for interaction.
4Interaction between non-HSV and HSV ulcers.
doi:10.1371/journal.pone.0022601.t004
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for 5 days), and lower than in Malawi (800 mg twice daily for 5
days); the duration of GUD before treatment was marginally
shorter in South Africa, but comparable to Ghana (median 5 days
vs. 7 days elsewhere); and ulcer characteristics were not different in
other respects (size and number) between South Africa and other
sites. Reported adherence was high in all three trials (.90% of
participants reporting having taken all their tablets by day 7),
although no information was available on drug concentrations,
nor on drug quality and storage. A limitation of the trials was that
the first visit date at which all patients were recalled was one week
after randomization, and we cannot evaluate impact on healing
within the first week. A number of possible explanations have been
put forward for the lack of efficacy of suppressive therapy on HIV
acquisition and transmission, which include the inadequacy of
current HSV treatment regimens to properly control HSV-2
replication itself [17]. It is possible that such a mechanism could
affect ulcer healing as well. In addition, these trials have shown
that African patients tend to come late for the management of
their ulcers, which would compromise the efficacy of antiviral
therapy. Clearly, earlier provision of more potent, and perhaps
more prolonged, HSV-2 therapies are required to control HSV-2
replication and hasten healing, particularly among HIV-positive
patients [27]. Earlier provision would be facilitated by counselling
of patients with recurrent genital herpes to improve symptom
recognition, as has been successful in the United States [28].
This pooled analysis provides descriptive data on a large series
of genital ulcer patients from four countries in sub-Saharan Africa.
Almost two-thirds of ulcers were due to HSV-2, and of these, a
quarter (225/918), were first-episode HSV-2 ulcers, representing
also 16% of all GUD. Only 10% of all ulcers had a bacterial
aetiology, alone or combined with HSV, although this varied by
country. HIV-1 prevalence was high in these populations (58%),
and a large proportion had CD4 counts below 200 cells/mm3,
while few individuals were on antiretroviral therapy at the time of
enrolment in 2003–2006.
The three trials were pragmatic trials designed to evaluate the
effectiveness of adding acyclovir to current syndromic management
of GUD, rather than the efficacy of acyclovir on treating herpetic
ulcers per se. Although it is clear that there was a benefit in South
Africa, the overall results suggest that there may be limited value in
adding acyclovir to GUD syndromic management in some other
African settings. Approximately seventeen GUD patients would
need to be treated with acyclovir for one additional patient to be
healed on day 7. There is likely to be some benefit in settings where
a high proportion of ulcers are genital herpes, especially first episode
HSV-2 ulcers which responded best to treatment, but this clinical
and lab-based information is rarely available in resource-poor
settings. The stronger effect among HIV-1 infected individuals than
HIV uninfected individuals overall also suggests that acyclovir may
be beneficial for GUD patients known to be HIV-infected at the
time of presentation to clinical services. The high prevalence in this
population highlights that genital ulceration in patient with
unknown HIV status provides a potential entry point for
provider-initiated HIV testing and care.
Figure 3. Time-to-ulcer-healing among all patients and those HIV-1 infected with HSV ulcers, by site.
doi:10.1371/journal.pone.0022601.g003
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It is not possible to diagnose HSV infection easily, quickly and
cheaply, let alone primary HSV-2 ulcers, with current tools in
resource-constrained clinical settings. Given the limited effective-
ness of adding acyclovir to syndromic management overall, and
the lack of clear reasons for why the regimen was more effective in
one trial than the other two, further research is needed to explore
better options for the management of GUD patients in sub-
Saharan Africa.
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